crypto_rage

bullish on $GPRO ? Added 4k shares - send it bulls

$IBRX adam and eve pattern... BULLISH

100% all in qubic-network:native

$IBRX im ready

Global expansion. Unstoppable

This weekend, we joined the @BladderCancerUS (BCAN) Walk in Los Angeles, coming together with a community united by strength, resilience, and shared purpose. Every step reflects the ongoing journey faced by those impacted by bladder cancer and the collective commitment to raising awareness and supporting one another along the way. Get involved in a walk near you: bcan.org/why-i-walk-to-…

As far back as 2019, Richard Pazdur, then head of OCE at FDA, recognized the importance of lymphocyte count in progression free survival and overall survival in lung cancer. I just discovered this paper today, just as I recently discovered the 2007 NCI workshop report showing the importance of T cell growth factor. He concludes that "baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC" meaning that whether the patient receives radiation, chemo, or checkpoint inhibitors, the level of lymphocyte count (ALC) is the critical biomarker for outcomes regardless of treatment modality. The Saudi FDA recognized this immediately and on that basis approved Anktiva for the treatment of 2nd line lung cancer who relapsed following standard of care. Pazdur further states "As further prospective clinical trial information is collected, the role of the LIPI score can be better defined." Stay tuned.

Access to innovative cancer therapies continues to expand. ANKTIVA® is now available in Saudi Arabia for patients with bladder and lung cancers, marking an important step in ImmunityBio’s global efforts to reach more patients. Read more: immunitybio.com/immunitybio-an…

After several months of development, we’re excited to announce that the bridge connecting @_Qubic_ to EVM is now live. Built and maintained by @Vottun, this bridge enables for the first time, the world’s fastest network to connect with the blockchain that brought smart contracts to life: @Ethereum. Two pioneering technologies now permanently connected. Let it flow 🌊 qubicbridge.com

A thousand patients a day ! An international center dedicated to the integrated next generation immunotherapy treatment of cancer in Portugal. Never seen anything like this. Full commitment from an amazing medical/ surgical leadership and the Health Ministry and government !

Last week, DOGE mining went live on Qubic.   Today, the walls come down.   QBridge hits mainnet. The first non-custodial bridge between Qubic and Ethereum.   Here's what that actually unlocks:   ➡️ QUBIC becomes wQUBIC on Ethereum. ERC-20. 1:1 backed. No middleman holding your bags. ➡️ Every DEX, lending protocol, and wallet on Ethereum is now open to Qubic holders. ➡️ 2-of-3 multisig. CertiK-audited. Built-in refund protection on every tx. ➡️ Cross-chain messaging for governance, oracles, and contract calls.   Qubic was an island. Not anymore.

One of the most sophisticated pancreatic cancer centers in the world I have had the honor to visit today.. in Europe! Change will happen here

$QUBIC patience will pay off - SUPER BULLISH

$IBRX inverse head&shoulder - stay strong bulls - 8s in tha house💪

April 1, is no longer a joke.

Qubic Doge mining is Not an April Fools joke. #DogeMeetsQubic

$IBRX $15 on table👀

$QUBIC ready for some BIG moves! SUPER BULLISH! #x1000

In less than 24 hours, DOGE mining goes live on Qubic. But it doesn't happen all at once. There's a 3-phase rollout designed to protect the network at every step: Phase 1: Test mode. XMR revenue unchanged. DOGE runs in the background proving the pipeline. Phase 2: Computors choose: XMR or DOGE. Incentives shift. Migration begins. Phase 3: XMR off. ASICs mine DOGE 24/7. CPUs/GPUs train AI 24/7. Full capacity. Zero compromise. This is a future-proof engineering plan. Watch the Video to Understand the Full Transition Plan:

What do you think about $QUBIC ? Decoupling from $BTC, mining with $DOGE I think $QUBIC will get his own BULLRUN!